New combo therapy aims to boost lung cancer survival
NCT ID NCT03110978
First seen Nov 03, 2025 · Last updated May 16, 2026 · Updated 24 times
Summary
This study tests whether adding an immunotherapy drug (nivolumab) to precise, high-dose radiation (SABR) helps keep early-stage non-small cell lung cancer from coming back. About 140 people with stage I-IIA or recurrent lung cancer will be randomly assigned to get radiation alone or radiation plus immunotherapy. The goal is to see if the combination improves event-free survival compared to radiation alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
MD Anderson West Houston
Houston, Texas, 77079, United States
-
MD Anderson in The Woodlands
Conroe, Texas, 77384, United States
Conditions
Explore the condition pages connected to this study.